Proactive Investors - Run By Investors For Investors

Zelda Therapeutics "ahead of the pack" in gaining first-mover advantages

Zelda Therapeutics Ltd (ASX:ZLD) executive chairman Harry Karelis updates Proactive Investors on the company’s global operations, following a January dual listing on the OTCQB Venture Market in the United States (OTCQB: ZLDAF).

“We have a two-pronged strategy. One is the clinical trials where we know there is some kind of effect, whether that's autism or pain or insomnia, so that's our clinical arm; and our pre-clinical arm is really spending money with some of the world's best researchers in studying cannabis as an anti-cancer agent… if we can replicate in the lab some of these anti-cancer effects then we believe that adds quite a lot of value for shareholders in Zelda in terms of then partnering with a traditional bio-pharmaceutical company... the data that we're generating and the intellectual property that we're developing is of value to those big bio-pharmaceutical companies that are geared up financially and otherwise for running these big complex trials," says Karelis.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
Meet West Wits Mining Limited, Global Energy Ventures Ltd, XTEK Ltd and ShareRoot Ltd at our event, Melbourne , 04 June 2019. Register here »
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use